Skip to content

MAGnetic marker TO detect primary lesion and sentinel node in breast cancer. The randomised MAGTOtal trial.

Tumour localization and sentinel lymph node identification using a magnetic localisation marker (Magseed) and super paramagnetic iron oxide nanoparticles (SiennaXP): The randomised MagTotal trial

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ISRCTN
Registry ID
ISRCTN11914537
Enrollment
200
Registered
2018-05-01
Start date
2018-04-01
Completion date
Unknown
Last updated
2026-06-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast cancer Cancer Breast cancer

Interventions

Patients partaking in the study will be allocated to marking of the tumour either with Magseed or a guidewire. Allocation will be performed with block randomisation using a block size of 10 and an all

Sponsors

Uppsala University
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to 100 Years

Inclusion criteria

Inclusion criteria: 1. Aged 18 years or older 2. Ductal carcinoma in situ (DCIS) or invasive breast cancer requiring localisation planned for primary surgery including sentinel node biopsy

Exclusion criteria

Exclusion criteria: 1. Intolerance or hypersensitivity to iron or dextran compounds or Sienna XP 2. Iron overload disease 3. Pacemaker or other implantable device in the chest-wall, or prosthesis in the shoulder 4. Deprived of liberty or under guardianship 5. Pregnant or lactating 6. Inability to provide informed consent

Design outcomes

Primary

MeasureTime frame
Radical excision, defined as free surgical margins of the specimen of the primary tumour according to preoperative diagnosis.

Secondary

MeasureTime frame
1. Width of margins per study arm in mm from the tumour to the resection margin both on specimen radiology and on final pathology. 2. Operative time from the beginning of the breast operation until the excision of the specimen in minutes. 3. Intraoperative and postoperative complications on 30 days, described by the Clavien Dindo classification and the Comprehensive Complication Index (CCI) (www.assessurgery.com). 4. Cost/benefit analysis based on the expenses of inpatient and outpatient care regarding the operation and 30 days of the postoperative period.

Countries

Sweden

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Jun 21, 2026